Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,463 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04129502 | TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations | active not recruiting | Phase 3 | 354 | TakedaINDUSTRY | 24 | Mar 30, 2026 | clinicaltrials |
| NCT05477576 | Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy(ACTION-1) | recruiting | Phase 3 | 338 | RayzeBio, Inc.INDUSTRY | 8 | Mar 30, 2026 |
| clinicaltrials |
| NCT07500701 | Salvage Moderate Hypofractionated Versus Ultrahypofractionated Radiotherapy for Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer | recruiting | Phase 3 | 270 | Samsung Medical CenterOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT05907122 | A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma | completed | Phase 3 | 256 | AmgenINDUSTRY | 22 | Mar 27, 2026 | clinicaltrials |
| NCT04003636 | Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)(KEYNOTE-966) | completed | Phase 3 | 1,069 | Merck Sharp & Dohme LLCINDUSTRY | 24 | Mar 24, 2026 | clinicaltrials |
| NCT04095364 | Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | active not recruiting | Phase 3 | 450 | NRG OncologyOTHER | 6 | Mar 24, 2026 | clinicaltrials |
| NCT04472598 | Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis(TRANSFORM-1) | completed | Phase 3 | 252 | AbbVieINDUSTRY | 25 | Mar 23, 2026 | clinicaltrials |
| NCT04211337 | A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer(LIBRETTO-531) | active not recruiting | Phase 3 | 291 | Loxo Oncology, Inc.INDUSTRY | 20 | Mar 19, 2026 | clinicaltrials |
| NCT04338269 | A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment(CONTACT-03) | terminated | Phase 3 | 522 | Hoffmann-La RocheINDUSTRY | 15 | Mar 19, 2026 | clinicaltrials |
| NCT05179889 | Adjuvant mFOLFIRINOX for High-risk Stage III Colon Cancer | recruiting | Phase 2 / Phase 3 | 308 | Chungnam National University HospitalOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT04948333 | Asciminib Treatment Optimization in ≥ 3rd Line CML-CP | completed | Phase 3 | 199 | Novartis PharmaceuticalsINDUSTRY | 16 | Mar 18, 2026 | clinicaltrials |
| NCT05654623 | A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer(VERITAC-2) | active not recruiting | Phase 3 | 624 | PfizerINDUSTRY | 31 | Mar 18, 2026 | clinicaltrials |
| NCT03164616 | Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).(POSEIDON) | active not recruiting | Phase 3 | 1,186 | AstraZenecaINDUSTRY | 19 | Mar 13, 2026 | clinicaltrials |
| NCT03142334 | Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564) | completed | Phase 3 | 994 | Merck Sharp & Dohme LLCINDUSTRY | 21 | Mar 10, 2026 | clinicaltrials |
| NCT03221426 | Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) | completed | Phase 3 | 1,007 | Merck Sharp & Dohme LLCINDUSTRY | 24 | Mar 9, 2026 | clinicaltrials |
| NCT04777851 | Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7(REPLACE) | terminated | Phase 3 | 45 | Translational Research in OncologyOTHER | 13 | Mar 9, 2026 | clinicaltrials |
| NCT05116189 | Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65). | active not recruiting | Phase 3 | 643 | Merck Sharp & Dohme LLCINDUSTRY | 25 | Mar 9, 2026 | clinicaltrials |
| NCT03036098 | Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer(CheckMate901) | active not recruiting | Phase 3 | 1,314 | Bristol-Myers SquibbINDUSTRY | 30 | Mar 6, 2026 | clinicaltrials |
| NCT01349322 | Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery | active not recruiting | Phase 3 | 2,354 | Radiation Therapy Oncology GroupNETWORK | 8 | Mar 5, 2026 | clinicaltrials |
| NCT04222972 | A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)(AcceleRET-Lung) | terminated | Phase 3 | 223 | Hoffmann-La RocheINDUSTRY | 22 | Mar 5, 2026 | clinicaltrials |
| NCT04494425 | Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer(DB-06) | active not recruiting | Phase 3 | 866 | AstraZenecaINDUSTRY | 28 | Mar 4, 2026 | clinicaltrials |
| NCT04819100 | A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)(LIBRETTO-432) | active not recruiting | Phase 3 | 152 | Eli Lilly and CompanyINDUSTRY | 32 | Mar 4, 2026 | clinicaltrials |
| NCT01712490 | A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma | completed | Phase 3 | 1,334 | TakedaINDUSTRY | 21 | Feb 27, 2026 | clinicaltrials |
| NCT01909453 | Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma(COLUMBUS) | completed | Phase 3 | 921 | PfizerINDUSTRY | 29 | Feb 27, 2026 | clinicaltrials |
| NCT03523585 | DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02] | completed | Phase 3 | 608 | Daiichi SankyoINDUSTRY | 15 | Feb 27, 2026 | clinicaltrials |
| NCT03675737 | Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859) | completed | Phase 3 | 1,579 | Merck Sharp & Dohme LLCINDUSTRY | 33 | Feb 27, 2026 | clinicaltrials |
| NCT06356311 | A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)(TroFuse-015) | active not recruiting | Phase 3 | 450 | Merck Sharp & Dohme LLCINDUSTRY | 24 | Feb 27, 2026 | clinicaltrials |
| NCT06532006 | A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer | recruiting | Phase 3 | 550 | Shanghai Henlius BiotechINDUSTRY | 17 | Feb 27, 2026 | clinicaltrials |
| NCT07437573 | Oncometabolic Surgery(KLASS-09) | completed | Phase 3 | 94 | Korea University Guro HospitalOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT03976362 | A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008) | completed | Phase 3 | 851 | Merck Sharp & Dohme LLCINDUSTRY | 20 | Feb 25, 2026 | clinicaltrials |
| NCT04697628 | Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer(innovaTV 301) | completed | Phase 3 | 502 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 25 | Feb 24, 2026 | clinicaltrials |
| NCT02811861 | Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma(CLEAR) | active not recruiting | Phase 3 | 1,069 | Eisai Inc.INDUSTRY | 20 | Feb 23, 2026 | clinicaltrials |
| NCT05171049 | A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE(ASTER) | terminated | Phase 3 | 1,150 | Anthos Therapeutics, Inc.INDUSTRY | 21 | Feb 23, 2026 | clinicaltrials |
| NCT04221945 | Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047) | completed | Phase 3 | 1,060 | Merck Sharp & Dohme LLCINDUSTRY | 30 | Feb 20, 2026 | clinicaltrials |
| NCT05386550 | Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION) | terminated | Phase 3 | 166 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 26 | Feb 19, 2026 | clinicaltrials |
| NCT03143153 | A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin(CheckMate 648) | completed | Phase 3 | 970 | Bristol-Myers SquibbINDUSTRY | 27 | Feb 17, 2026 | clinicaltrials |
| NCT07413120 | Efficacy and Safety of VasoClip® vs. WeckClip® for Robotic Urologic Surgery | completed | Phase 3 | 40 | Incheon St.Mary's HospitalOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT02000622 | Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.(OlympiAD) | completed | Phase 3 | 302 | AstraZenecaINDUSTRY | 19 | Feb 13, 2026 | clinicaltrials |
| NCT05827523 | Interval Cytoreductive Surgery With or Without HIPEC for Ovarian Cancer (FOCUS / KOV-HIPEC-04)(FOCUS / KOV-04) | recruiting | Phase 3 | 520 | National Cancer Center, KoreaOTHER_GOV | 1 | Feb 13, 2026 | clinicaltrials |
| NCT01460589 | Early Commencement of Adjuvant Chemotherapy for Colon Cancer(ECTX) | active not recruiting | Phase 3 | 303 | Kyungpook National University HospitalOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT05316181 | CRS & HIPEC for Platinum-Resistant Recurrent Ovarian Cancer (KOV-02R, RECOVER)(KOV-HIPEC-02R) | active not recruiting | Phase 3 | 140 | National Cancer Center, KoreaOTHER_GOV | 1 | Feb 12, 2026 | clinicaltrials |
| NCT03426904 | Neoadjuvant FOLFOX Chemotherapy for Patients With Locally Advanced Colon Cancer | active not recruiting | Phase 3 | 708 | Kyungpook National University HospitalOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT05415215 | A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer(ProHer) | completed | Phase 3 | 346 | Hoffmann-La RocheINDUSTRY | 17 | Feb 10, 2026 | clinicaltrials |
| NCT05501886 | Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)(VIKTORIA-1) | active not recruiting | Phase 3 | 701 | Celcuity IncINDUSTRY | 23 | Feb 10, 2026 | clinicaltrials |
| NCT06435429 | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | recruiting | Phase 3 | 550 | Jazz PharmaceuticalsINDUSTRY | 15 | Feb 10, 2026 | clinicaltrials |
| NCT03275285 | Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients(IKEMA) | completed | Phase 3 | 302 | SanofiINDUSTRY | 16 | Feb 9, 2026 | clinicaltrials |
Data updated 24 days agoSource updated unknownsource: clinicaltrials